- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06448637
DRUGSLIPPENDE BALL vs. FARMAKOAKTIV STENT I STORE BAR: MORFOLOGISK ANALYSE OG FUNKSJONSVASOMOTOR (DEBORA STUDIE) I STORE BAR: MORFOLOGISK ANALYSE OG FUNKSJONSVASOMOTOR (DEBORA STUDIE)
DRUGSLIPPENDE BALL vs. FARMAKOAKTIV STENT I STORE FAR: MORFOLOGISK ANALYSE OG FUNKSJONSVASOMOTOR (DEBORA STUDY)
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: FUNDACION EPIC
- Telefonnummer: 0034987876135
- E-post: iepic@fundacionepic.org
Studer Kontakt Backup
- Navn: IÑIGO LOZANO MARTINEZ-LUENGAS, MD, PhD
- Telefonnummer: 0034630901145
- E-post: inigo.lozano@fundacionepic.org
Studiesteder
-
-
-
Barcelona, Spania, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
Gijón, Spania, 33394
- Rekruttering
- Hospital Universitario de Cabueñes
-
Huelva, Spania, 21005
- Rekruttering
- Hospital Universitario Juan Ramón Jiménez
-
León, Spania, 24008
- Rekruttering
- Hospital Universitario de Leon
-
Lugo, Spania, 270003
- Rekruttering
- Hospital Universitario Lucus Augusti
-
Mérida, Spania, 06800
- Rekruttering
- Hospital de Merida
-
Oviedo, Spania, 33011
- Rekruttering
- Hospital Universitario Central de Asturias
-
Pontevedra, Spania, 36071
- Rekruttering
- Hospital Provincial de Pontevedra
-
Tarragona, Spania, 43005
- Rekruttering
- Hospital Universitari de Tarragona Joan XXIII
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Patients who meet all of the following conditions are included.
- Patients aged ≥ 18 years and;
- Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and;
- Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and;
- Patients who have been informed of the characteristics of the study and have provided their written informed consent.
Exclusion Criteria:
Patients who meet at least one of the following conditions are excluded:
- Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG).
- Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery.
- Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion.
- Patients who received a combination of DES and DCB in the same vessel
- Patients with glomerular filtration rate <30 ml/min/ 1.73 m2
- Patients with body mass index >35 (may affect the evaluation qualitative diameter of the coronary artery).
- Patients with symptomatic congestive heart failure.
- Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids).
- Patients with heart transplant.
- Patients with anemia (Hb <12 g/dL in men and <10 g/dL in women).
- Patients, women of childbearing age with a positive pregnancy test.
- Pregnant female patients.
- Patients included in other clinical trials with active follow-up.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Drug Coated Balloon (DCB)
Drug Coated Balloon (DCB) |
Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI) |
|
Eksperimentell: Drug Eluting Stent (DES)
Drug Eluting Stent (DES) |
Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of vessels with a positive response to Ach, defined as >4% change in the mean luminal diameter observed in the coronary segment distal (10-30 mm) to the treated segment, after the infusion of the maximum dose of ACh (10-6 mol/L).
Tidsramme: 8 months
|
Percentage of vessels with a positive response to Ach, defined as >4% change in the mean luminal diameter observed in the coronary segment distal (10-30 mm) to the treated segment, after the infusion of the maximum dose of ACh (10-6 mol/L). |
8 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparison of percentage of angiographic restenosis by quantitative coronary
Tidsramme: 8 months
|
Comparison of percentage of angiographic restenosis by quantitative coronary |
8 months
|
|
Comparison of the minimum luminal diameter of the treated segment by optical coronary tomography
Tidsramme: 8 months
|
Comparison of the minimum luminal diameter of the treated segment by optical coronary tomography |
8 months
|
|
Comparison of the minimum luminal area of the treated segment by optical coronary tomography
Tidsramme: 8 months
|
Comparison of the minimum luminal area of the treated segment by optical coronary tomography |
8 months
|
|
Percentage of of strut coverage by OCT(Optical Coherence Tomography) in the DES group
Tidsramme: 8 months
|
Percentage of of strut coverage by OCT in the DES group |
8 months
|
|
Percentage of vessels with normal vascular architecture with correct definition of intima and media by optical coherence tomography in the drug-coated balloon group at 8 months
Tidsramme: 8 months
|
Percentage of vessels with normal vascular architecture with correct definition of intima and media by optical coherence tomography in the drug-coated balloon group at 8 months |
8 months
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 10;75(9):1061-1073. doi: 10.1016/j.jacc.2019.12.046.
- Nakamura T, Brott BC, Brants I, Panchal D, Li J, Chen JP, King SB 3rd, Chronos N, Hou D. Vasomotor function after paclitaxel-coated balloon post-dilation in porcine coronary stent model. JACC Cardiovasc Interv. 2011 Feb;4(2):247-55. doi: 10.1016/j.jcin.2010.08.028.
- Gutierrez E G-LJ, Escaned J, Cruz I, Ojeda S, Romaguera R, Moreno R. Valoración de la función endotelial y provocación de vasoespasmo coronario mediante infusión intracoronaria de acetilcolina. Documento técnico de la ACI-SEC. REC Interv Cardiol. 2021;3(4):286-296.
- Gomez-Lara J, Oyarzabal L, Ortega-Paz L, Brugaletta S, Romaguera R, Salvatella N, Roura G, Rivero F, Fuentes L, Alfonso F, Otaegui I, Vandeloo B, Vaquerizo B, Sabate M, Comin-Colet J, Gomez-Hospital JA. Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. J Am Heart Assoc. 2021 Nov 16;10(22):e022123. doi: 10.1161/JAHA.121.022123. Epub 2021 Nov 3.
- Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012 Jun;33(11):1325-33. doi: 10.1093/eurheartj/ehr466. Epub 2012 Apr 16.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EPIC37-DEBORA
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .